2023
Evolving systemic management of urothelial cancers
Tan W, Tan M, Alhalabi O, Campbell M, Kamat A, Gao J. Evolving systemic management of urothelial cancers. Current Opinion In Oncology 2023, 35: 186-199. PMID: 36966497, DOI: 10.1097/cco.0000000000000942.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Transitional CellHumansImmune Checkpoint InhibitorsImmunoconjugatesImmunotherapyUrinary Bladder NeoplasmsConceptsPlatinum-based chemotherapyInvasive bladder cancerBladder cancerAntibody-drug conjugatesFibroblast growth factor receptorCheckpoint inhibitorsUrothelial carcinomaProgrammed cell death-ligand 1 inhibitorsLocalized muscle invasive bladder cancerImprove bladder cancer outcomesNonmuscle invasive bladder cancerTraditional platinum-based chemotherapyProgrammed cell death 1Management of urothelial carcinomaMuscle invasive bladder cancerImmune checkpoint inhibitorsCell death 1Third-line optionBladder cancer outcomesResponse to therapyGrowth factor receptorFood and Drug AdministrationDeath-1Second-lineSystemic treatment
2022
A gender-related dichotomy in bladder cancer.
Cimadamore A, Teoh J, DI Trapani E, Krajewski W, Tan W, Mori K, Del Giudice F, Carrion D, Moschini M. A gender-related dichotomy in bladder cancer. Minerva Urologica E Nefrologica 2022, 74: 376-378. PMID: 35607787, DOI: 10.23736/s2724-6051.22.04954-0.Peer-Reviewed Original Research
2019
Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis
Jubber I, Shariat S, Conroy S, Tan W, Gordon P, Lotan Y, Messing E, Stenzl A, Rhijn B, Kelly J, Catto J, Cumberbatch M. Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. European Urology 2019, 77: 583-598. PMID: 31791622, DOI: 10.1016/j.eururo.2019.10.010.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Transitional CellHematuriaHumansKidney NeoplasmsUreteral NeoplasmsUrinary Bladder NeoplasmsConceptsNon-visible haematuriaUpper tract urothelial carcinomaMeta-analysisSystematic reviewKidney cancerSystematic review of original articlesUrological cancersRisk of cancerIncidence of cancerReview of original articlesCancer detection rateRe-evaluation of patientsPublic health implicationsBladder cancerNarrative synthesisDiagnosis of BCInclusion criteriaMeta-analysesCigarette smokingHealth implicationsDiagnosis of bladder cancerMale sexEstimated riskHigh-risk patientsGroup of individuals
2018
Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy
Moschini M, Soria F, Mathieu R, Xylinas E, D'Andrea D, Tan W, Kelly J, Simone G, Tuderti G, Meraney A, Krishna S, Konety B, Zamboni S, Baumeister P, Mattei A, Briganti A, Montorsi F, Galucci M, Rink M, Karakiewicz P, Rouprêt M, Aziz A, Perry M, Rowe E, Koupparis A, Kassouf W, Scherr D, Ploussard G, Boorjian S, Sooriakumaran P, Shariat S, Urologists U. Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. Urologic Oncology Seminars And Original Investigations 2018, 37: 179.e1-179.e7. PMID: 30446442, DOI: 10.1016/j.urolonc.2018.10.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Transitional CellChemotherapy, AdjuvantCystectomyFemaleFollow-Up StudiesHumansLength of StayLymph Node ExcisionMaleMargins of ExcisionMiddle AgedPostoperative ComplicationsPropensity ScoreRetrospective StudiesRobotic Surgical ProceduresTreatment OutcomeUrinary BladderUrinary Bladder NeoplasmsConceptsSoft tissue surgical marginsRobotic-assisted radical cystectomyOpen radical cystectomyPositive soft tissue surgical marginsRARC groupSoft tissue surgical margin statusRadical cystectomyPropensity-score matchingRARC patientsOpen radical cystectomy groupImpact of surgical techniqueOpen radical cystectomy patientsNon-organ-confinedMultivariate logistic regression analysisOrgan-confined diseaseSurgical margin statusSubgroup of patientsPropensity-score-matched cohortLogistic regression analysisOncologic efficacySurgical marginsPrognostic factorsUrothelial carcinomaMargin statusSurgical techniqueBOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapyDoes urinary cytology have a role in haematuria investigations?
Tan W, Sarpong R, Khetrapal P, Rodney S, Mostafid H, Cresswell J, Watson D, Rane A, Hicks J, Hellawell G, Davies M, Srirangam S, Dawson L, Payne D, Williams N, Brew‐Graves C, Feber A, Kelly J, Sridhar A, Lamb B, Ocampo F, McBain H, Baillie K, Middleton K, Knight H, Maher S, Pathmanathan B, Harmathova A, Pelluri S, Pati J, Cossons A, Scott C, Madaan S, Bradfield S, Wakeford N, Dann, Cook J, Cornwell M, Mills R, Thomas, Reyner S, Vallejera G, Adeniran P, Masood S, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Hheeney E, Green K, Evans S, Rogers M, Gupwell K, ley S, Brown A, McGrath J, Lunt N, Hill P, inclair A, Paredes‐Guerra A, Holbrook B, Ong E, Wardle H, Wilson D, Bayles A, Fennelly R, Tribbeck M, Ames K, Taylor J, Edmunds E, Moore J, Mckinley S, Nolan T, peed A, Tunnicliff A, Fossey G, Williams A, George M, Hutchins I, Einosas R, Richards A, Henderson A, Appleby B, Kehoe L, Gladwell L, Drakeley S, Davies J, Krishnan R, Roberts H, Main C, Jain S, Dumville J, Wilkinson N, Taylor J, Thomas F, Goulden K, Vinod C, Green E, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Rees A, Williams S, Dukes S, Goffe A, Mistry R, Chadwick J, Cocks S, Hull R, oftus A, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Storr E, Cogley L, Natale S, Lovegrove W, Slack K, Nash D, Smith K, Walsh J, Guerdette A, Hill M, Taylor B, Sinclair E, Perry M, Debbarma M, Hewitt D, Sriram R, Power A, Cannon J, Devereaux L, Thompson A, Atkinson K, Royle L, Madine J, MacLean K. Does urinary cytology have a role in haematuria investigations? BJU International 2018, 123: 74-81. PMID: 30003675, PMCID: PMC6334509, DOI: 10.1111/bju.14459.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Transitional CellFalse Negative ReactionsFalse Positive ReactionsFemaleHematuriaHumansKidney NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingPredictive Value of TestsProspective StudiesTomography, X-Ray ComputedUltrasonographyUreteral NeoplasmsUrinary Bladder NeoplasmsUrineUrographyConceptsUpper tract urothelial cancerPositive urine cytologyAccuracy of urinary cytologyDiagnosis of bladder cancerUrine cytologyHigh-risk cancerNegative predictive valuePositive predictive valueBladder cancerHaematuria investigationsUrinary cytologyInvasive testingDiagnostic accuracy of urinary cytologyMuscle-invasive bladder cancerProspective observational study of patientsMulticentre prospective observational studyObservational study of patientsPredictive valueEndoscopic tumor resectionPositive cytology resultsUpper tract imagingHigh-risk diseaseOutcomes of patientsDiagnosed bladder cancerStudy of patients
2015
Robot‐assisted intracorporeal pyramid neobladder
Tan W, Sridhar A, Goldstraw M, Zacharakis E, Nathan S, Hines J, Cathcart P, Briggs T, Kelly J. Robot‐assisted intracorporeal pyramid neobladder. BJU International 2015, 116: 771-779. PMID: 26033321, DOI: 10.1111/bju.13189.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Transitional CellCystectomyFemaleFollow-Up StudiesHumansMaleMiddle AgedOperative TimePostoperative ComplicationsRoboticsTreatment OutcomeUrinary Bladder NeoplasmsUrinary DiversionConceptsRobot-assisted radical cystectomyMuscle-invasive bladder cancerUrinary tract infectionPostoperative complicationsFunctional outcomesMedian estimated blood lossNight time continenceBilateral pelvic lymphadenectomyEstimated blood lossMedian hospital stayRecurrence-free survivalUpper tract imagingMedian follow-upLate postoperative complicationsEarly postoperative complicationsPort-site herniaUretero-ileal strictureVitamin B12 deficiencyBlocked stentsNeobladder stonePelvic lymphadenectomyOncological outcomesRadical cystectomyOverall survivalBlood loss